Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1

Interventions

fludarabine phosphate 20 Peripheral Blood Stem Cell Transplantation 20 Cyclophosphamide 17 Busulfan 16 ruxolitinib 14 Tacrolimus 12 Whole-Body Irradiation 9 Mycophenolic Acid 9 Methotrexate 8 Antilymphocyte Serum 8 Cyclosporine 7 peginterferon alfa-2a 6 Hydroxyurea 6 Filgrastim 6 Etoposide 6 Aspirin 6 fludarabine 5 Prednisone 5 Melphalan 5 Imatinib Mesylate 5 Cytarabine 5 Decitabine 4 pomalidomide 3 givinostat hydrochloride 3 givinostat 3 Topotecan 3 Thiotepa 3 Radiotherapy 3 Lenalidomide 3 Carboplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Polycythemia Vera × bomedemstat × Clear all

NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed

20 enrolled 19 charts

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon ⚡